Compare KD & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | KRYS |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 7.8B |
| IPO Year | 2021 | 2017 |
| Metric | KD | KRYS |
|---|---|---|
| Price | $12.36 | $248.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $35.25 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 4.7M | 254.5K |
| Earning Date | 05-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.95 | 128.00 |
| EPS | 0.77 | ★ 6.84 |
| Revenue | ★ $15,057,000,000.00 | $389,130,000.00 |
| Revenue This Year | $3.96 | $40.88 |
| Revenue Next Year | $0.41 | $35.16 |
| P/E Ratio | ★ $16.31 | $36.71 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $10.10 | $123.03 |
| 52 Week High | $43.74 | $298.30 |
| Indicator | KD | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 38.23 |
| Support Level | $11.34 | $233.64 |
| Resistance Level | $13.81 | $248.60 |
| Average True Range (ATR) | 0.51 | 9.14 |
| MACD | 0.45 | -2.19 |
| Stochastic Oscillator | 42.98 | 9.64 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.